{"id":"W2897369942","doi":"10.1158/1078-0432.ccr-18-2014","title":"A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors","year":2018,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Cancer Foundation","funders":"AbbVie","keywords":"Veliparib; Carboplatin; Medicine; Etoposide; Internal medicine; Tolerability; Oncology; Pharmacokinetics; Chemotherapy; Pharmacology; Adverse effect; Surgery; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00152109,0.0002249615,0.0007819926,0.0002773933,0.0001601971,0.00003331428,0.0001369179,0.00009813926,0.00007630039],"category_scores_gemma":[0.0003990012,0.0001509765,0.0000281577,0.0006655385,0.001297807,0.00008473406,0.0002542741,0.0008364676,0.000001200919],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002414867,"about_ca_system_score_gemma":0.0006873666,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00797167,"about_ca_topic_score_gemma":0.01585223,"domain_scores_codex":[0.9965677,0.0004035649,0.0006384692,0.0007225983,0.001059466,0.000608173],"domain_scores_gemma":[0.9971013,0.0006285072,0.0001772193,0.0004293711,0.001336232,0.0003273859],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02353952,0.002839552,0.9665294,0.0004083154,0.0002162818,0.00003921237,0.002819113,0.000009755403,0.0001743514,0.000005214113,0.0002304958,0.003188761],"study_design_scores_gemma":[0.04678887,0.02986974,0.9192827,0.000799334,0.0001080802,6.126006e-7,0.001328169,0.0009497101,0.0005812052,0.000006980207,0.0001046962,0.0001798986],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949991,0.000770959,0.000004203159,0.0003957126,0.0000460536,0.003355591,0.00004892122,0.00001739826,0.0003620362],"genre_scores_gemma":[0.9985129,0.0002108428,0.00008135827,0.0001385325,0.0001540669,0.0004355146,0.000004679491,0.00005155732,0.0004106024],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04724672,"threshold_uncertainty_score":0.9986343,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1209327320517012,"score_gpt":0.5074382325365686,"score_spread":0.3865055004848674,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}